ENALAPRIL MALEATE (Orodispersible tablet - Aqumeldi)

Clinical Indication

Treatment of heart failure in children from birth to less than 18 years.


Not licensed in Adults

Date of classification

May 2024


Shared Care Agreement. Higher risk medicines requiring significant regular monitoring which would be initiated by or at the recommendation of a specialist service which may include mental health services, secondary care, tertiary care, community providers, private providers and GPs with a specialist interest.